FDMT vs. VIR, TARS, CGEM, NMRA, SRRK, BCRX, AUTL, IMTX, PROK, and INBX
Should you be buying 4D Molecular Therapeutics stock or one of its competitors? The main competitors of 4D Molecular Therapeutics include Vir Biotechnology (VIR), Tarsus Pharmaceuticals (TARS), Cullinan Oncology (CGEM), Neumora Therapeutics (NMRA), Scholar Rock (SRRK), BioCryst Pharmaceuticals (BCRX), Autolus Therapeutics (AUTL), Immatics (IMTX), ProKidney (PROK), and Inhibrx (INBX). These companies are all part of the "biological products, except diagnostic" industry.
4D Molecular Therapeutics (NASDAQ:FDMT) and Vir Biotechnology (NASDAQ:VIR) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their valuation, institutional ownership, profitability, community ranking, earnings, media sentiment, dividends, risk and analyst recommendations.
In the previous week, 4D Molecular Therapeutics had 12 more articles in the media than Vir Biotechnology. MarketBeat recorded 17 mentions for 4D Molecular Therapeutics and 5 mentions for Vir Biotechnology. Vir Biotechnology's average media sentiment score of 0.96 beat 4D Molecular Therapeutics' score of 0.55 indicating that Vir Biotechnology is being referred to more favorably in the news media.
4D Molecular Therapeutics has higher earnings, but lower revenue than Vir Biotechnology. 4D Molecular Therapeutics is trading at a lower price-to-earnings ratio than Vir Biotechnology, indicating that it is currently the more affordable of the two stocks.
Vir Biotechnology received 5 more outperform votes than 4D Molecular Therapeutics when rated by MarketBeat users. However, 65.38% of users gave 4D Molecular Therapeutics an outperform vote while only 48.15% of users gave Vir Biotechnology an outperform vote.
4D Molecular Therapeutics has a net margin of -436.30% compared to Vir Biotechnology's net margin of -677.69%. 4D Molecular Therapeutics' return on equity of -26.75% beat Vir Biotechnology's return on equity.
4D Molecular Therapeutics currently has a consensus target price of $44.22, indicating a potential upside of 70.87%. Vir Biotechnology has a consensus target price of $33.57, indicating a potential upside of 238.76%. Given Vir Biotechnology's higher probable upside, analysts plainly believe Vir Biotechnology is more favorable than 4D Molecular Therapeutics.
4D Molecular Therapeutics has a beta of 2.94, meaning that its share price is 194% more volatile than the S&P 500. Comparatively, Vir Biotechnology has a beta of 0.47, meaning that its share price is 53% less volatile than the S&P 500.
99.3% of 4D Molecular Therapeutics shares are owned by institutional investors. Comparatively, 65.3% of Vir Biotechnology shares are owned by institutional investors. 7.3% of 4D Molecular Therapeutics shares are owned by company insiders. Comparatively, 15.6% of Vir Biotechnology shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Summary
4D Molecular Therapeutics beats Vir Biotechnology on 12 of the 18 factors compared between the two stocks.
Get 4D Molecular Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for FDMT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding FDMT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
4D Molecular Therapeutics Competitors List
Related Companies and Tools
